Skip to main content
. 2009 Mar;4(3):579–587. doi: 10.2215/CJN.04030808

Figure 2.

Figure 2.

Patient 16: Evolution of CD19+ and CD20+ cells, and of rituximab-specific human antichimeric antibodies (HACAs) after treatment with rituximab (RTX) and cyclophosphamide (CYP). Full arrows: injection of RTX (375 mg/m2 of body surface area). Empty arrows: injection of CYP (500 mg).